Rigel's PROTAC Pivot: A New Growth Gear in Breast Cancer

Q2 2026: Strong results, the in-license of VEPPANU, and a clear path to a diversified commercial oncology platform.

RIGL · Earnings Call · 2026-08-04

A Transformative Quarter

Rigel Pharmaceuticals has long been known as a focused hematology player, but the Q2 2026 earnings call made it unmistakable: the company is becoming a diversified commercial oncology platform. As CEO Raul Rodriguez put it, “The Q2 was an excellent one and marked an important step in Rigel's transformation into a diversified commercial oncology and hematology company.” — Raul R. Rodriguez, Chief Executive Officer · 2026-08-04 The linchpin is the exclusive global license of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for second-line or later ER-positive, HER2-negative, ESR1-mutated metastatic Breast Cancer. This move instantly adds a massive addressable market and a novel mechanism of action, setting Rigel apart from its traditional ITP and AML franchises. The strategic shift was not improvised. For over a year, management has been telegraphing its intent to bolt on late-stage assets. On the March 2026 call, Rodriguez told investors, “We are in a fortunate place that many opportunities that are out there are in the order of magnitude in terms of the size that would be appropriate for us.” — Raul Rodriguez, President and Chief Executive Officer · 2026-03-03 The VEPPANU deal is the fruition of that strategy, and it comes with substantial near-term catalysts. The company's commercial portfolio now spans four products, and the sales force has been retrained in record time to carry the new message.

The VEPPANU Opportunity: Data and Launch Readiness

VEPPANU is not just another endocrine therapy; it is a first-in-class heterobifunctional protein degrader. Chief Commercial Officer David Santos emphasized its potential: “we believe moving forward that VEPPANU has the potential to become Rigel's largest revenue producer.” — David A. Santos, Chief Commercial Officer · 2026-08-04 The pivotal VERITAC-2 trial delivered a striking efficacy signal. Chief Medical Officer Alison Hannah summarized the headline: “Median PFS was 5.0 months for those patients receiving vepdegestrant, where it was only 2.1 months for those patients receiving fulvestrant.” — Alison L. Hannah, Chief Medical Officer · 2026-08-04 The hazard ratio of 0.57 (p<0.001) and a more than quadrupled objective response rate (18.6% vs. 4%) underline the drug's differentiation in a setting where patients have exhausted standard options. The market opportunity is substantial. Using a conservative estimate of ~20,000 eligible second-line and later ESR1-mutated patients annually in the U.S., management pegs the market at more than $1 billion. They also highlight the community practice opportunity: nearly 80% of metastatic breast cancer patients are treated in community settings, and oral SERDs have already captured ~60% share in the second-line setting, signaling clinician willingness to adopt newer oral agents. Rigel's infrastructure is ready: RIGEL ONECARE is live, the sales team is trained, and commercial availability is scheduled for mid-August, ahead of internal expectations.

Our strategy is centered on four core strategic objectives: grow our commercial business, expand our product portfolio and pipeline through in-licensing or acquisition, advance our development pipeline in the clinic, and maintain financial discipline.
Raul R. Rodriguez, Chief Executive Officer · 2026-08-04

Financial and Operational Momentum

The move into breast cancer is supported by a business that is already profitable and growing. In Q2 2026, Rigel reported $67 million in U.S. net product sales, up 14% year-over-year, and net income of $17.3 million. The company raised its 2026 revenue guidance to $285–$295 million, excluding VEPPANU, while reiterating its commitment to positive net income. This financial strength gives Rigel the runway to fund the $70 million upfront payment and up to $40 million in development contributions for VEPPANU without jeopardizing its balance sheet. Net income of $17.3 million in Q2 compares to $59.6 million in the year-ago quarter, which included a $40 million non-cash collaboration gain. The underlying trend is what matters: the company is now sustainably profitable, a sharp contrast to its cash-burn history. Investors have clearly noticed. The stock is up over 57% in the last 90 days, reflecting growing confidence in the VEPPANU launch and the broader pipeline. Prior management commentary on business development—“So really, it's a good data set with that final dose group, having data from that final dose group, which we're eager to share.” — Raul Rodriguez, Chief Executive Officer · 2025-11-04—about R289 in lower-risk MDS, shows that the company is also building a deeper pipeline, with dose-expansion readouts expected by year-end. The combination of a new commercial pillar and a promising clinical asset positions Rigel for sustained growth through the decade and beyond. The transformation is not without risk—VEPPANU faces entrenched competitors and reimbursement hurdles, and the launch cadence remains to be seen. But Rigel's execution on in-licensing, its financial discipline, and the clear medical need in this patient population make this a compelling story. The second half of 2026 will be a defining test, and the company appears ready.